| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | ALKB DC |
| ISIN code | DK0061802139 |
| Industry group | Pharmaceuticals and biotechnology |
| Aligned with SDGs |
ALK-Abelló is a Danish-based company specializing in the development of allergy treatment products and is recognized as the global leader in the allergy immunotherapy market. Its portfolio includes injections (subcutaneous immunotherapy), under-the-tongue drops (sublingual immunotherapy), and tablet treatments addressing all major respiratory allergies, such as pollen, house dust mites, and Japanese cedar. The company’s products are used by millions of patients worldwide. Founded in Denmark in 1923, ALK-Abelló has been at the forefront of allergy research, introducing several scientific breakthroughs, including the first tablet-based allergy vaccine against grass pollen in Europe. The company is headquartered in Hørsholm, Denmark.
Investment rationale
ALK improves access to diagnostics and treatments for respiratory allergies. According to the European Academy of Allergy and Clinical Immunology (EAACI), allergies are considered one of the most common chronic conditions in Europe, and their prevalence is rising. Many children suffer from allergy-related sleep and cognitive function impairments, reduced academic performance and restricted ability to participate in sport and other activities. ALK promotes greater access to allergy care by covering additional patient populations and it makes available allergy treatments for children in Japan, Europe and North America.
Besides the positive impact of its products and promoting greater access to allergy care, ALK also engages systematically in educational activities, training and dialogue with healthcare professionals to enhance insights into diagnosis and treatment of allergic disease.
Alignment with Triodos transitions:
100% of revenues is aligned with the Wellbeing transition. The contribution to the Wellbeing transition comes from 100% of revenues related to the impact objective Health Care.